173 related articles for article (PubMed ID: 35147073)
21. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.
Li CI; Daling JR; Haugen KL; Tang MT; Porter PL; Malone KE
Breast Cancer Res Treat; 2014 Jun; 145(2):481-9. PubMed ID: 24748570
[TBL] [Abstract][Full Text] [Related]
22. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
[TBL] [Abstract][Full Text] [Related]
23. Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspective.
Rozenberg S; Panay N; Gambacciani M; Cano A; Gray S; Schaudig K
Expert Rev Clin Pharmacol; 2023; 16(6):507-517. PubMed ID: 37278023
[TBL] [Abstract][Full Text] [Related]
24. Menopause hormone treatment after cancer.
Gompel A
Climacteric; 2023 Jun; 26(3):240-247. PubMed ID: 37011657
[TBL] [Abstract][Full Text] [Related]
25. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
Simon JA; Nahum GG; Stanislaw H; Gaines T
Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk.
Flores VA; Taylor HS
Endocrinol Metab Clin North Am; 2015 Sep; 44(3):587-602. PubMed ID: 26316245
[TBL] [Abstract][Full Text] [Related]
27. Menopausal hormone therapy (MHT): refining our understanding of MHT research, optimally applying results, and considering the future of MHT.
Anagnostis EA
J Pharm Pract; 2012 Jun; 25(3):324-30. PubMed ID: 22550160
[TBL] [Abstract][Full Text] [Related]
28. The use of menopausal hormone therapy after cancer.
Brennan A; Hickey M
Best Pract Res Clin Obstet Gynaecol; 2022 May; 81():22-30. PubMed ID: 34920970
[TBL] [Abstract][Full Text] [Related]
29. The association between menopausal hormone therapy and breast cancer remains unsettled.
Fillon M
CA Cancer J Clin; 2024; 74(3):210-212. PubMed ID: 38720557
[No Abstract] [Full Text] [Related]
30. Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors.
Clarke CA; Purdie DM; Glaser SL
BMC Cancer; 2006 Jun; 6():170. PubMed ID: 16803628
[TBL] [Abstract][Full Text] [Related]
31. Underlying Breast Cancer Risk and Menopausal Hormone Therapy.
Santen RJ; Heitjan DF; Gompel A; Lumsden MA; Pinkerton JV; Davis SR; Stuenkel CA
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32052007
[TBL] [Abstract][Full Text] [Related]
32. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials.
Greiser CM; Greiser EM; Dören M
Hum Reprod Update; 2005; 11(6):561-73. PubMed ID: 16150812
[TBL] [Abstract][Full Text] [Related]
33. [Menopause and hormone replacement therapy].
Tóth KS
Orv Hetil; 2000 Mar; 141(11):547-56. PubMed ID: 10741167
[TBL] [Abstract][Full Text] [Related]
34. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
35. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.
Mendoza N; Ramírez I; de la Viuda E; Coronado P; Baquedano L; Llaneza P; Nieto V; Otero B; Sánchez-Méndez S; de Frutos VÁ; Andraca L; Barriga P; Benítez Z; Bombas T; Cancelo MJ; Cano A; Branco CC; Correa M; Doval JL; Fasero M; Fiol G; Garello NC; Genazzani AR; Gómez AI; Gómez MÁ; González S; Goulis DG; Guinot M; Hernández LR; Herrero S; Iglesias E; Jurado AR; Lete I; Lubián D; Martínez M; Nieto A; Nieto L; Palacios S; Pedreira M; Pérez-Campos E; Plá MJ; Presa J; Quereda F; Ribes M; Romero P; Roca B; Sánchez-Capilla A; Sánchez-Borrego R; Santaballa A; Santamaría A; Simoncini T; Tinahones F; Calaf J
Maturitas; 2022 Dec; 166():65-85. PubMed ID: 36081216
[TBL] [Abstract][Full Text] [Related]
36. [Hormone replacement therapy in menopause and risk of breast cancer].
Clavel-Chapelon F; Hill C
Presse Med; 2000 Oct; 29(31):1688-93. PubMed ID: 11094609
[TBL] [Abstract][Full Text] [Related]
37. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
38. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
39. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Jones ME; Schoemaker MJ; Wright L; McFadden E; Griffin J; Thomas D; Hemming J; Wright K; Ashworth A; Swerdlow AJ
Br J Cancer; 2016 Aug; 115(5):607-15. PubMed ID: 27467055
[TBL] [Abstract][Full Text] [Related]
40. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
